Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer--preliminary results of a randomized trial.

Patients with advanced colorectal cancer were randomized to receive either fluorouracil (5-FU) 370 mg/m2 IV days 1 to 5 followed by weekly applications of 5-FU 600 mg/m2 or the same doses of 5-FU preceded by folinic acid 200 mg/m2. Because of toxicity, the weekly 5-FU dose in the combination treatment schedule was reduced to 500 mg/m2 in the course of the study. As of November 1990, 135 patients entered the study; 71 have received combination therapy, and 64 monotherapy.

[Clinical-histological correlation and significance of duodenitis (author's transl)].

In 200 patients with upper abdominal complaints biopsy material was taken by fiberoptic endoscopy for histologic evaluation. Histology was normal in both the gastric fractions from fundus and antrum and from the duodenal mucosa in 53 cases. 36 Patients showed the histologic picture of duodenitis with leucocytic infiltrates of the villous stroma in the vicinity of erosions or ulcerations.

[A contribution as to the effect of (+)-Cyanidanol-3 in chronic liver disease (author's transl)].

In an open controlled multicenter study the effectiveness of various dose levels of (+)-Cyanidanol-3 (Catergen) in patients suffering from chronic liver disease and treated over a period of 6 months is assessed. Subjective symptoms as fatigue, nausea, loss of appetite, vomiting and pruritus are positively influenced at all dose levels. A statistically significant fall of the transaminases SGOT, SGPT and gamma--GT however occurs only at a dosage of 6 tablets per day (3000 mg per day) of (+)-Cyanidanol-3, which cannot be demonstrated at a dose level of 3 X 1 tablet per day.